Search research articles
Contact Us
Filters
Showing results (1-10 of 97) with videos related to
Page
of 10
Sort By:
Best Practice & Research. Clinical Haematology
|
March 12, 2025
CAR assembly line: Taking CAR T-cell manufacturing to the next level
Jiasheng Wang, Paolo F Caimi
Expert Opinion on Biological Therapy
|
September 10, 2021
Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma
Krishna Goparaju, Paolo F Caimi
Current Oncology Reports
|
May 24, 2019
Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach
Kirsten M Boughan, Paolo F Caimi
Seminars in Oncology
|
February 26, 2014
The "paradigm of abundance" in clinical oncology practice: a new agony and ecstasy?
Hillard M Lazarus, Paolo F Caimi
Blood Reviews
|
November 10, 2023
A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma
Taylor R Brooks, Paolo F Caimi
Blood Advances
|
March 11, 2025
CAR T-cell reality for R/R LBCL: challenges and challengers
Paolo F Caimi, Craig S Sauter
Revista Brasileira De Hematologia E Hemoterapia
|
March 14, 2014
Genetic polymorphisms, chronic lymphocytic leukemia, and the future: are we there yet?
Paolo F Caimi, Marcos de Lima
Cancer Immunology Research
|
April 2, 2024
Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models
Paolo F Caimi, Jan Joseph Melenhorst
Therapeutic Advances in Hematology
|
August 6, 2016
Bortezomib for the treatment of mantle cell lymphoma: an update
Bryan Hambley, Paolo F Caimi, Basem M William
Transplantation and Cellular Therapy
|
May 7, 2026
Step-Specific Activation Timelines for Cellular Therapy Clinical Trials: A Decade of Regulatory Improvement and Persistent Financial Bottlenecks
Joseph Farinella, Stephanie Farlow, Claudio Brunstein, et al.
Page
of 10
Search research articles
Search
Showing results (1-10 of 97) with videos related to
Sort By:
Page
of 10
Best Practice & Research. Clinical Haematology
|
March 12, 2025
CAR assembly line: Taking CAR T-cell manufacturing to the next level
Jiasheng Wang, Paolo F Caimi
Expert Opinion on Biological Therapy
|
September 10, 2021
Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma
Krishna Goparaju, Paolo F Caimi
Current Oncology Reports
|
May 24, 2019
Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach
Kirsten M Boughan, Paolo F Caimi
Seminars in Oncology
|
February 26, 2014
The "paradigm of abundance" in clinical oncology practice: a new agony and ecstasy?
Hillard M Lazarus, Paolo F Caimi
Blood Reviews
|
November 10, 2023
A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma
Taylor R Brooks, Paolo F Caimi
Blood Advances
|
March 11, 2025
CAR T-cell reality for R/R LBCL: challenges and challengers
Paolo F Caimi, Craig S Sauter
Revista Brasileira De Hematologia E Hemoterapia
|
March 14, 2014
Genetic polymorphisms, chronic lymphocytic leukemia, and the future: are we there yet?
Paolo F Caimi, Marcos de Lima
Cancer Immunology Research
|
April 2, 2024
Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models
Paolo F Caimi, Jan Joseph Melenhorst
Therapeutic Advances in Hematology
|
August 6, 2016
Bortezomib for the treatment of mantle cell lymphoma: an update
Bryan Hambley, Paolo F Caimi, Basem M William
Transplantation and Cellular Therapy
|
May 7, 2026
Step-Specific Activation Timelines for Cellular Therapy Clinical Trials: A Decade of Regulatory Improvement and Persistent Financial Bottlenecks
Joseph Farinella, Stephanie Farlow, Claudio Brunstein, et al.
Page
of 10